HIV Glasgow 2014

aidsmap news from HIV Glasgow 2014

• Restoring and maintaining a high CD4 count possible for vast majority of people living with HIV in France

  Treatment outcomes and life expectancy
  Alain Volny-Anne | 12 November 2014

  A large French study has shown that the vast majority of people living with HIV who started treatment since 2000 in a national cohort achieved a CD4 cell count in the normal ...

• Once-daily dolutegravir superior to darunavir/ritonavir in 96-week follow-up

  New and experimental HIV treatments
  Alain Volny-Anne | 10 November 2014

  Treatment with a triple antiretroviral combination containing once-daily integrase inhibitor dolutegravir (Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir (Prezista) over 96 weeks of follow-up, Jean-Michel Molina of the Hôpital Saint Louis, ...

• Doravirine works as well as efavirenz with fewer CNS side-effects

  New and experimental HIV treatments
  Liz Highleyman | 10 November 2014

  Once-daily doravirine (MK-1439), an experimental NNRTI, demonstrated viral suppression similar to that of efavirenz at 48 weeks, and the dose selected for further development was associated with fewer central nervous system (CNS) side-effects, ...

• Protease inhibitor monotherapy: darunavir/ritonavir less effective than three-drug therapy

  Changing treatment
  Keith Alcorn | 07 November 2014

  Darunavir/ritonavir monotherapy results in a lower rate of viral suppression after 48 weeks when compared to darunavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs), but may be just as effective as ...

• Truvada PrEP use rising in United States, especially among men

  PrEP
  Liz Highleyman | 07 November 2014

  The number of people using Truvada for pre-exposure prophylaxis (PrEP) in the US is increasing and a growing proportion of users are men, according to an analysis of data from approximately half of ...

• One third of TB cases in Eastern European HIV clinic survey multi-drug resistant

  Drug-resistant TB
  Alain Volny-Anne | 05 November 2014

  Around one-third of people living with HIV in Eastern Europe who were diagnosed with tuberculosis (TB) had multidrug-resistant TB, according to the findings of a global study of TB and HIV ...

• Australia performs best in HIV treatment cascade – 62% with undetectable viral load

  Retention and linkage to care
  Keith Alcorn | 04 November 2014

  Australia and northern European countries are doing far better than North America at retaining people living with HIV in care and achieving viral suppression, according to a comprehensive survey of 'treatment cascades' in ...

• Generic antiretrovirals could save NHS £1.25 billion over 5 years, study finds

  Generic medicines
  Michael Carter | 04 November 2014

  Switching all patients taking antiretrovirals in the United Kingdom to generic versions of the drugs they are taking, if available, would save around £1.25 billion between 2015 and 2019, according to an analysis ...

• Efavirenz compromises hormonal contraceptive implant

  Contraception
  Keith Alcorn | 03 November 2014

  The widely prescribed non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz substantially reduces levels of the hormonal contraceptive levonorgestrel, a component of a progesterone contraceptive implant widely used in developing countries, according to findings from ...

• Do emtricitabine and lamivudine have similar virological efficacy when used in first-line HIV therapy?

  Treatment guidelines
  Michael Carter | 03 November 2014

  First-line antiretroviral regimens containing emtricitabine have superior virological efficacy to combinations containing lamivudine when combined with tenofovir and either nevirapine or efavirenz, Dutch investigators report in the online edition of Clinical Infectious Diseases.The findings ...